Broadly Neutralizing Antibodies for HIV Eradication (Q28073939)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26841901%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

2 references

25 October 2022

10 January 2024

Broadly Neutralizing Antibodies for HIV Eradication (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26841901%20AND%20SRC:MED&resulttype=core&format=json

human immunodeficiency virus infectious disease

7 March 2020

main subject

1 reference

envelope glycoprotein GP120

31 August 2020

viral envelope proteins

1 reference

2 August 2019

1 reference

27 September 2019

1 reference

3 November 2019

1 reference

20 November 2019

1 reference

23 December 2019

1 reference

31 August 2020

neutralizing antibody

1 reference

19 January 2021

language of work or name

1 reference

1 February 2016

16 references

23 March 2019

2 August 2019

27 September 2019

19 October 2019

3 November 2019

20 November 2019

27 November 2019

13 December 2019

23 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26841901%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

28 April 2020

1 July 2020

31 August 2020

19 January 2021

25 October 2022

10 January 2024

Current HIV/AIDS reports

17 references

23 March 2019

2 August 2019

27 September 2019

19 October 2019

3 November 2019

20 November 2019

27 November 2019

13 December 2019

23 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26841901%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

28 April 2020

1 July 2020

31 August 2020

19 January 2021

25 October 2022

10 January 2024

13

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26841901%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

31-37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26841901%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26841901%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

7 March 2020

copyright license

15 references

23 March 2019

2 August 2019

27 September 2019

19 October 2019

3 November 2019

20 November 2019

27 November 2019

13 December 2019

23 December 2019

28 April 2020

1 July 2020

31 August 2020

19 January 2021

25 October 2022

on focus list of Wikimedia project

10 January 2024

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7

0 references

cites work

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Broad neutralization coverage of HIV by multiple highly potent antibodies

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Immunologic strategies for HIV-1 remission and eradication

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Passive Immunotherapy in AIDS: A Randomized Trial of Serial Human Immunodeficiency Virus-Positive Transfusions of Plasma Rich in p24 Antibodies versus Transfusions of Seronegative Plasma

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-016-0299-7

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-016-0299-7

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-016-0299-7

A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-016-0299-7

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-016-0299-7

Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. The Passive Hyperimmune Therapy Study Group.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779134

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

27 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/26841901

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11904-016-0299-7

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26841901%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

7 March 2020

1005667407

0 references

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26841901%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26841901%20AND%20SRC:MED&resulttype=core&format=json